Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Corcept Therapeutics, now recruiting.
Overview
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT07276373 by Corcept Therapeutics, with 50 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09. Interventions recorded: Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg and Nivolumab.
Similar pages
not linked directly; found by shared links- TrialStudy BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialRelacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Shares Corcept Therapeutics and the tag pipeline.
- TrialACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialRelacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Shares Corcept Therapeutics and the tag pipeline.
- TrialA Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.